Actively Recruiting
Mass Balance Study of [14C] ABBV-932 Following Single Oral Dose in Healthy Adult Male Volunteers
Led by AbbVie · Updated on 2026-06-02
8
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and tolerability of ABBV-932 in healthy adult male participants. This Phase 1 study focuses on how the body absorbs, processes, and eliminates a single oral dose of ABBV-932, a drug given to volunteers without any known health conditions. The study is sponsored by AbbVie and aims to gather important data on the drug’s behavior in the body. Participants will receive one oral dose of ABBV-932 on the first day of the study. The trial is designed to observe this single administration without any placebo or comparison group. The study period includes monitoring for up to approximately 86 days to assess drug levels and effects over time. During the study, participants will undergo various assessments including measuring the maximum concentration of ABBV-932 in the blood, the time it takes to reach this peak level, and how quickly the drug is eliminated from the body. Researchers will also track any adverse events for up to around 103 days after dosing. Participation will last over this extended period to ensure thorough safety and tolerability evaluations.
CONDITIONS
Brief Title
A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Body Mass Index (BMI) between 18.0 and 29.9 kg/m2 after rounding to the tenths decimal
- Male participant who is not considering fathering a child or donating sperm during the study and for 100 days after study drug administration
- General good health based on medical history and physical exam
You will not qualify if you...
- Participation in another radiolabeled drug absorption, distribution, metabolism, excretion (ADME) study with a radiodose above 0.1 MBq within 12 months prior to screening
- Use of medications or products that alter drug absorption, metabolism, or excretion within 30 days or 5 half-lives prior to study drug administration
- Prior exposure to ABBV-932 or cariprazine within the past 90 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive a single oral dose of ABBV-932.
1 dosing visit (in-person)
Duration - Up to approximately 103 days
Participants are monitored for up to approximately 103 days to assess drug concentration and adverse events.
Multiple visits for pharmacokinetic sampling and safety assessments
Trial Site Locations
Total: 1 location
1
ICON Clinical Research /ID# 270490
Groningen, Netherlands, 9728 NZ
Actively Recruiting
Research Team
A
ABBVIE CALL CENTER
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here